×

Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers

  • US 10,500,259 B2
  • Filed: 12/21/2017
  • Issued: 12/10/2019
  • Est. Priority Date: 08/05/2015
  • Status: Active Grant
First Claim
Patent Images

1. A method of eliciting an immune response in a patient who has cancer, comprising administering to the patient a population of activated T cells that selectively recognize cells which present a peptide consisting of the amino acid sequence of HLLEDIAHV (SEQ ID NO:

  • 3),wherein the activated T cells are produced by contacting T cells with the peptide loaded human class I or II MEW molecules expressed on the surface of an antigen-presenting cell for a period of time sufficient to activate the T cells;

    wherein said cancer is selected from the group consisting of liver cancer, breast cancer, uterine cancer, gallbladder cancer, bile duct cancer, acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), ovarian cancer, and esophageal cancer.

View all claims
  • 1 Assignment
Timeline View
Assignment View
    ×
    ×